来自杂志 The Lancet. Infectious diseases 的文献。
当前共找到 1 篇文献分享。
1.
李翛然
(2022-12-28 21:08):
#paper doi:10.1016/S1473-3099(22)00291-2 Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2022 Aug 8:S1473-3099(22)00291-2. . 这篇文章非常好的梳理了正在北美和欧洲大杀四方的rsv 病毒疫苗研发情况。 现在国门打开，未来必然是新冠+rsv+流感的轮流爆发，我司准备开一个这个管线。这篇综述写的非常好。 很有参考价值的梳理了技术路线，临床阶段，为我们的布局很有指导性意义。
Abstract:
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a …
>>>
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory syncytial virus vaccine or immunoprophylaxis remain highly active. 33 respiratory syncytial virus prevention candidates are in clinical development using six different approaches: recombinant vector, subunit, particle-based, live attenuated, chimeric, and nucleic acid vaccines; and monoclonal antibodies. Nine candidates are in phase 3 clinical trials. Understanding the epitopes targeted by highly neutralising antibodies has resulted in a shift from empirical to rational and structure-based vaccine and monoclonal antibody design. An extended half-life monoclonal antibody for all infants is likely to be within 1 year of regulatory approval (from August, 2022) for high-income countries. Live-attenuated vaccines are in development for older infants (aged >6 months). Subunit vaccines are in late-stage trials for pregnant women to protect infants, whereas vector, subunit, and nucleic acid approaches are being developed for older adults. Urgent next steps include ensuring access and affordability of a respiratory syncytial virus vaccine globally. This review gives an overview of respiratory syncytial virus vaccines and monoclonal antibodies in clinical development highlighting different target populations, antigens, and trial results.
<<<
翻译